These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25658304)

  • 1. Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?
    Cowan R; Athan E; Friedman ND; Hughes AJ; McDonald A; Callan P; Fyfe J; O'Brien DP
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003503. PubMed ID: 25658304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort.
    Friedman ND; Athan E; Hughes AJ; Khajehnoori M; McDonald A; Callan P; Rahdon R; O'Brien DP
    PLoS Negl Trop Dis; 2013; 7(7):e2315. PubMed ID: 23875050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients.
    O'Brien DP; Friedman D; Hughes A; Walton A; Athan E
    Intern Med J; 2017 Sep; 47(9):1011-1019. PubMed ID: 28585259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort.
    Friedman ND; Athan E; Walton AL; O'Brien DP
    Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.
    O'Brien DP; Friedman ND; McDonald A; Callan P; Hughes A; Walton A; Athan E
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006357. PubMed ID: 29554101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin.
    Dossou AD; Sopoh GE; Johnson CR; Barogui YT; Affolabi D; Anagonou SY; Zohoun T; Portaels F; Asiedu K
    Med J Aust; 2008 Nov; 189(9):532-3. PubMed ID: 18976206
    [No Abstract]   [Full Text] [Related]  

  • 10. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
    Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium ulcerans culture results according to duration of prior antibiotic treatment: A cohort study.
    Tweedale B; Collier F; Waidyatillake NT; Athan E; O'Brien DP
    PLoS One; 2023; 18(4):e0284201. PubMed ID: 37093836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
    Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors Associated with Antibiotic Treatment Failure of Buruli Ulcer.
    O'Brien DP; Friedman ND; Walton A; Hughes A; Athan E
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six vs Eight Weeks of Antibiotics for Small Mycobacterium ulcerans Lesions in Australian Patients.
    O'Brien DP; Friedman ND; Cowan R; Walton A; Athan E
    Clin Infect Dis; 2020 Apr; 70(9):1993-1997. PubMed ID: 31231766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buruli ulcer in an 18-day-old baby.
    Kiiza AM; Wood PB
    Trop Doct; 2012 Jan; 42(1):48. PubMed ID: 22080481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Mycobacterium ulcerans cytochrome bc
    Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
    Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.